Medrad receives FDA clearance for NaF PET infusion system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Medrad, a unit of Bayer HealthCare, has received FDA clearance to market its Intego PET infusion system for 18F-Sodium Fluoride (NaF) administration in PET imaging to find and assess bone metastases.

According to the Warrendale, Pa.-based Medrad, Intego is the only multi-PET agent infusion system currently cleared by the FDA, and Medrad received FDA clearance for 18F-FDG administration in 2008.

The 18F-NaF PET imaging is covered by the Centers for Medicare & Medicaid Services for beneficiaries under coverage with evidence development program.